The Administrative Core will be critical in providing overall leadership and central administrative support to the Chemistry Center, including establishing and implementing, in collaboration with center staff, assay providers and the NIH Network Science Officer, a Compound Probe Development Plan (CPDP) for each program. One of the most critical functions of the Administrative Core will be communication with other Centers within the MLPCN, including coordination of studies, transfer of compounds, and efficient communication of data to facilitate iterative compound synthesis and testing. In addition, the Administrative Core will be responsible for organization for all Center meetings, travel arrangements for attendance of MLPCN meetings, preparation of progress reports and noncompetitive renewal applications. Finally, the administrative core will be responsible for recruitment and staffing as well as budgetary management of the Program. The following specific aims summarize the major functions of the administrative core:
AIM 1. To establish goals of each probe optimization effort and initiate probe optimization by assigning lead chemist and coordinating communication between the Vanderbilt chemistry center, other MLPCN centers, the MLSMR, and the NIH program administrators.
AIM 2. To effectively manage the integration of activities of medicinal chemistry, informatics and pharmacology components within the Vanderbilt Specialized Chemistry Center.
AIM 3. To coordinate and manage communication and transfer of reagents, data and novel probes to the scientific community.
AIM 4. To recruit and maintain staff for the proposed MLPCN facility to support and advance the MLPCN goals.
|Wood, Michael R; Noetzel, Meredith J; Poslusney, Michael S et al. (2017) Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Bioorg Med Chem Lett 27:171-175|
|Gogliotti, Rocco G; Senter, Rebecca K; Fisher, Nicole M et al. (2017) mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Sci Transl Med 9:|
|Long, Madeline F; Engers, Julie L; Chang, Sichen et al. (2017) Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorg Med Chem Lett 27:4999-5001|
|Bender, Aaron M; Weiner, Rebecca L; Luscombe, Vincent B et al. (2017) Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists. Bioorg Med Chem Lett 27:3576-3581|
|Bender, Aaron M; Weiner, Rebecca L; Luscombe, Vincent B et al. (2017) Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype. Bioorg Med Chem Lett 27:2479-2483|
|Melancon, Bruce J; Wood, Michael R; Noetzel, Meredith J et al. (2017) Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. Bioorg Med Chem Lett 27:2296-2301|
|Oliver, Kendra H; Duvernay, Matthew T; Hamm, Heidi E et al. (2016) Loss of Serotonin Transporter Function Alters ADP-mediated Glycoprotein ?IIb?3 Activation through Dysregulation of the 5-HT2A Receptor. J Biol Chem 291:20210-9|
|Witt, Jonathan O; McCollum, Andrea L; Hurtado, Miguel A et al. (2016) Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonists. Bioorg Med Chem Lett 26:2481-8|
|Wu, Yang; Stauffer, Shaun R; Stanfield, Robyn L et al. (2016) Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen-Fluorogen Activating Protein Binding Pair. J Biomol Screen 21:74-87|
|Garcia-Barrantes, Pedro M; Cho, Hyekyung P; Starr, Tahj M et al. (2016) Re-exploration of the mGlu? PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR. Bioorg Med Chem Lett 26:2289-92|
Showing the most recent 10 out of 144 publications